UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 333

Sortiert nach

Psychedelic drug abuse potential assessment for new drug applications and controlled substance scheduling: A United States perspective

Journal of psychopharmacology (Oxford), 2023-01, Vol.37 (1), p.33-44

2023

Link zum Volltext

Verfügbarkeit prüfen

Kratom Abuse Potential 2021: An Updated Eight Factor Analysis

Frontiers in pharmacology, 2022-01, Vol.12, p.775073-775073

2022

Link zum Volltext

Verfügbarkeit prüfen

Understanding Kratom Use: A Guide for Healthcare Providers

Frontiers in pharmacology, 2022-03, Vol.13, p.801855-801855

2022

Link zum Volltext

Verfügbarkeit prüfen

A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor

Journal of psychopharmacology (Oxford), 2018-12, Vol.32 (12), p.1351-1361

2018

Link zum Volltext

Verfügbarkeit prüfen

Psychedelics: Where we are now, why we got here, what we must do

Neuropharmacology, 2018-11, Vol.142, p.7-19

2018

Link zum Volltext

Verfügbarkeit prüfen

The novel uncompetitive NMDA receptor antagonist esmethadone (REL-1017) has no meaningful abuse potential in recreational drug users

Translational psychiatry, 2023-06, Vol.13 (1), p.192-12, Article 192

2023

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of the abuse potential of difelikefalin, a selective kappa‐opioid receptor agonist, in recreational polydrug users

Clinical and translational science, 2022-02, Vol.15 (2), p.535-547

2022

Link zum Volltext

Verfügbarkeit prüfen

Advancing equity, diversity, and inclusion in the American College of Neuropsychopharmacology (ACNP): advances, challenges, and opportunities to accelerate progress

Neuropsychopharmacology (New York, N.Y.), 2021-04, Vol.46 (5), p.871-876

2021

Link zum Volltext

Verfügbarkeit prüfen

The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act

Neuropharmacology, 2018-11, Vol.142, p.143-166

2018

Link zum Volltext

Verfügbarkeit prüfen

Abuse Liability Assessment of Tobacco Products Including Potential Reduced Exposure Products

Cancer epidemiology, biomarkers & prevention, 2009-12, Vol.18 (12), p.3241-3262

2009

Link zum Volltext

Verfügbarkeit prüfen

Reply to Drs. Hart and Cadet: we agree-the challenges of increasing equity, diversity and inclusion include societal issues and actions now are vital

Neuropsychopharmacology (New York, N.Y.), 2021-04, Vol.46 (5), p.878-879

2021

Link zum Volltext

Verfügbarkeit prüfen

Pain management strategies and lessons from the military: A narrative review

Pain research & management, 2015-09, Vol.20 (5), p.261-268

2015

Link zum Volltext

Verfügbarkeit prüfen

The abuse potential of kratom according the 8 factors of the controlled substances act: implications for regulation and research

Psychopharmacology, 2018-02, Vol.235 (2), p.573-589

2018

Link zum Volltext

Verfügbarkeit prüfen

Reducing the nicotine content to make cigarettes less addictive

Tobacco control, 2013-05, Vol.22 (suppl 1), p.i14-i17

2013

Link zum Volltext

Verfügbarkeit prüfen

Current and Future Potential Impact of COVID-19 on Kratom ( Mitragyna speciosa Korth.) Supply and Use

Frontiers in psychiatry, 2020-11, Vol.11, p.574483-574483

2020

Link zum Volltext

Verfügbarkeit prüfen

The tobacco endgame: It's all about behavior

Preventive medicine, 2014-11, Vol.68, p.11-16

Henningfield, Jack E

2014

Link zum Volltext

Verfügbarkeit prüfen

The abuse potential of lemborexant, a dual orexin receptor antagonist, according to the 8 factors of the Controlled Substances Act

Psychopharmacology, 2023-04, Vol.240 (4), p.699-711

2023

Link zum Volltext

Verfügbarkeit prüfen

We Need Better Estimates of Kratom Use Prevalence

American journal of preventive medicine, 2022-01, Vol.62 (1), p.132-133

2022

Link zum Volltext

Verfügbarkeit prüfen

Nicotine Reduction Strategy: State of the science and challenges to tobacco control policy and FDA tobacco product regulation

Preventive medicine, 2018-12, Vol.117, p.5-7

2018

Link zum Volltext

Verfügbarkeit prüfen

In Memoriam Roy W. Pickens 1939–2022

Psychopharmacology, 2022-08, Vol.239 (8), p.2373-2375

2022

Link zum Volltext

Verfügbarkeit prüfen

Respiratory effects of oral mitragynine and oxycodone in a rodent model

Psychopharmacology, 2022-12, Vol.239 (12), p.3793-3804

2022

Link zum Volltext

Verfügbarkeit prüfen

Kratom as a substitute for opioids: Results from an online survey

Drug and alcohol dependence, 2019-09, Vol.202, p.24-32

2019

Link zum Volltext

Verfügbarkeit prüfen

Abuse liability assessment of the JUUL system in four flavors relative to combustible cigarette, nicotine gum and a comparator electronic nicotine delivery system among adult smokers

Drug and alcohol dependence, 2020-12, Vol.217, p.108395, Article 108395

2020

Link zum Volltext

Verfügbarkeit prüfen

An Open-Label, Randomised, Controlled, Crossover Study to Assess Nicotine Pharmacokinetics and Subjective Effects of the JUUL System with Three Nicotine Concentrations Relative to Combustible Cigarettes in Adult Smokers

Nicotine & tobacco research, 2021-06, Vol.23 (6), p.947-955

2021

Link zum Volltext

Verfügbarkeit prüfen

Risk of death associated with kratom use compared to opioids

Preventive medicine, 2019-11, Vol.128, p.105851-105851, Article 105851

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 333

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(317)
Mit Volltextzugriff
(282)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(333)
Japanisch
(14)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Psychedelic drug abuse potential assessment for new drug applications and controlled substance scheduling: A United States perspective

Kratom Abuse Potential 2021: An Updated Eight Factor Analysis

Understanding Kratom Use: A Guide for Healthcare Providers

A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor

Psychedelics: Where we are now, why we got here, what we must do

The novel uncompetitive NMDA receptor antagonist esmethadone (REL-1017) has no meaningful abuse potential in recreational drug users

Evaluation of the abuse potential of difelikefalin, a selective kappa‐opioid receptor agonist, in recreational polydrug users

Advancing equity, diversity, and inclusion in the American College of Neuropsychopharmacology (ACNP): advances, challenges, and opportunities to accelerate progress

The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act

Abuse Liability Assessment of Tobacco Products Including Potential Reduced Exposure Products

Reply to Drs. Hart and Cadet: we agree-the challenges of increasing equity, diversity and inclusion include societal issues and actions now are vital

Pain management strategies and lessons from the military: A narrative review

The abuse potential of kratom according the 8 factors of the controlled substances act: implications for regulation and research

Reducing the nicotine content to make cigarettes less addictive

Current and Future Potential Impact of COVID-19 on Kratom ( Mitragyna speciosa Korth.) Supply and Use

The tobacco endgame: It's all about behavior

The abuse potential of lemborexant, a dual orexin receptor antagonist, according to the 8 factors of the Controlled Substances Act

We Need Better Estimates of Kratom Use Prevalence

Nicotine Reduction Strategy: State of the science and challenges to tobacco control policy and FDA tobacco product regulation

In Memoriam Roy W. Pickens 1939–2022

Respiratory effects of oral mitragynine and oxycodone in a rodent model

Kratom as a substitute for opioids: Results from an online survey

Abuse liability assessment of the JUUL system in four flavors relative to combustible cigarette, nicotine gum and a comparator electronic nicotine delivery system among adult smokers

An Open-Label, Randomised, Controlled, Crossover Study to Assess Nicotine Pharmacokinetics and Subjective Effects of the JUUL System with Three Nicotine Concentrations Relative to Combustible Cigarettes in Adult Smokers

Risk of death associated with kratom use compared to opioids

Suchergebnisse filtern